Profile data is unavailable for this security.
About the company
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.
- Revenue in USD (TTM)0.00
- Net income in USD-5.34m
- Incorporated2004
- Employees4.00
- LocationARCA Biopharma Inc10170 Church Ranch Way, Suite 100WESTMINSTER 80021United StatesUSA
- Phone+1 (720) 940-2200
- Fax+1 (302) 655-5049
- Websitehttps://arcabio.com/
Mergers & acquisitions
| Acquired company | ABIO:NAQ since announced | Transaction value |
|---|---|---|
| Oruka Therapeutics Inc | 109.36% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Modular Medical Inc | 0.00 | -16.76m | 46.48m | 37.00 | -- | 8.31 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
| Jaguar Health Inc | 9.76m | -41.30m | 46.96m | 49.00 | -- | 2.52 | -- | 4.81 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
| Movano Inc | 0.00 | -29.28m | 47.59m | 30.00 | -- | 7.85 | -- | -- | -0.6463 | -0.6463 | 0.00 | 0.0618 | 0.00 | -- | -- | 0.00 | -258.41 | -151.50 | -496.87 | -188.58 | -- | -- | -- | -- | 1.26 | -- | 0.014 | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Journey Medical Corp | 79.18m | -3.85m | 48.76m | 58.00 | -- | 3.32 | -- | 0.6158 | -0.3502 | -0.3502 | 4.19 | 1.05 | 0.8701 | 2.19 | 3.65 | 1,365,190.00 | -4.23 | -- | -10.51 | -- | 66.33 | -- | -4.87 | -- | 1.10 | 0.6863 | 0.4641 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 49.79m | 29.00 | -- | 3.96 | -- | 902.40 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -40.33m | 50.12m | 20.00 | -- | 0.5863 | -- | -- | -1.82 | -1.82 | 0.00 | 3.45 | 0.00 | -- | -- | 0.00 | -44.35 | -38.44 | -47.03 | -39.80 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 54.16 | -- | -- | -- |
| Arca Biopharma Inc | 0.00 | -5.34m | 50.46m | 4.00 | -- | 1.36 | -- | -- | -0.3704 | -0.3704 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -13.19 | -27.78 | -13.49 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 50.62m | 729.00 | -- | 0.4053 | -- | 0.2936 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Checkpoint Therapeutics Inc | 103.00k | -51.85m | 50.67m | 23.00 | -- | -- | -- | 491.99 | -2.93 | -2.93 | 0.0055 | -0.4703 | 0.011 | -- | -- | 4,478.26 | -555.46 | -142.43 | -- | -342.79 | -- | -- | -50,336.89 | -6,554.97 | -- | -- | -- | -- | -46.35 | -50.61 | 17.21 | -- | -- | -- |
| Avrobio Inc | 0.00 | 12.16m | 53.16m | 13.00 | 4.30 | 0.5585 | 4.16 | -- | 0.2756 | 0.2756 | 0.00 | 2.12 | 0.00 | -- | -- | 0.00 | 11.86 | -45.22 | 13.10 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 53.81m | 5.00 | -- | 4.09 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Cable Car Capital LLCas of 22 Jan 2024 | 4.00m | 27.59% |
| Western Standard LLCas of 31 Dec 2023 | 1.41m | 9.72% |
| Adage Capital Management LPas of 03 Apr 2024 | 1.20m | 8.28% |
| Janus Henderson Investors UK Ltd.as of 03 Apr 2024 | 1.08m | 7.45% |
| Allostery Investments LPas of 15 Apr 2024 | 1.07m | 7.34% |
| Avidity Partners Management LPas of 03 Apr 2024 | 1.00m | 6.90% |
| BML Capital Management LLCas of 31 Dec 2023 | 706.93k | 4.88% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 453.60k | 3.13% |
| Newtyn Management LLCas of 31 Dec 2023 | 269.32k | 1.86% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 231.91k | 1.60% |
